Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc

Science

Volumn 320, Issue 5874, 2008, Pages 373-376

  Anthony, Robert M ^a   Nimmerjahn, Falk ^a,d   Ashline, David J ^b   Reinhold, Vernon N ^b   Paulson, James C ^c   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF NEW HAMPSHIRE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; LECTIN; SIALIC ACID;

IMMUNE RESPONSE; PLASMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOGLOBULIN STRUCTURE; MACROPHAGE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIALYLATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; CARBOHYDRATE CONFORMATION; GALACTOSE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; N-ACETYLNEURAMINIC ACID; POLYSACCHARIDES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECOMBINANT PROTEINS;

EID: 42349085035     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1154315     Document Type: Article

References (25)

1. A. Samuelsson, T. L. Towers, J. V. Ravetch, Science 291, 484 (2001).
2. P. Bruhns, A. Samuelsson, J. W. Pollard, J. V. Ravetch, Immunity 18, 573 (2003).
3. Y. Kaneko, F. Nimmerjahn, M. P. Madaio, J. V. Ravetch, J. Exp. Med. 203, 789 (2006).
4. Y. Kaneko, F. Nimmerjahn, J. V. Ravetch, Science 313, 670 (2006).
5. F. Nimmerjahn, J. V. Ravetch, J. Exp. Med. 204, 11 (2007).
6. N. Takahashi et al., Biochemistry 26, 1137 (1987).
7. Materials and methods are available as supporting material on Science Online.
8. A. S. Korganow et al., Immunity 10, 451 (1999).
9. M. Dalziel, I. McFarlane, J. S. Axford, Glycoconj. J. 16, 801 (1999).
10. J. N. Arnold, M. R. Wormald, R. B. Sim, P. M. Rudd, R. A. Dwek, Annu. Rev. Immunol. 25, 21 (2007).
11. T. Hennet, D. Chui, J. C. Paulson, J. D. Marth, Proc. Natl. Acad. Sci. U.S.A. 95, 4504 (1998).
12. J. N. Arnold et al., J. Immunol. 173, 6831 (2004).
13. H. Kitagawa, J. C. Paulson, J. Biol. Chem. 269, 17872 (1994).
14. R. Jefferis et al., Biochem. J. 268, 529 (1990).
15. M. R. Wormald et al., Biochemistry 36, 1370 (1997).
16. B. J. Scallon, S. H. Tam, S. G. McCarthy, A. N. Cai, T. S. Raju, Mol. Immunol. 44, 1524 (2007).
17. A. Varki, Nature 446, 1023 (2007).
18. F. Lehmann, E. Tiralongo, J. Tiralongo, Cell. Mol. Life Sci. 63, 1331 (2006).
19. T. M. Tumpey et al., Science 315, 655 (2007).
20. A. Ibricevic et al., J. Virol. 80, 7469 (2006).
21. F. G. Hanisch, J. Hacker, H. Schroten, Infect. Immun. 61, 2108 (1993).
22. D. C. Mayer, O. Kaneko, D. E. Hudson-Taylor, M. E. Reid, L. H. Miller, Proc. Natl. Acad. Sci. U.S.A. 98, 5222 (2001).
23. P. A. Orlandi, F. W. Klotz, J. D. Haynes, J. Cell Biol. 116, 901 (1992).
24. F. Nimmerjahn, J. V. Ravetch, Science 310, 1510 (2005).
25. We thank P. Smith, A. Miguelez, A. Magracheva, and J. Pagan for excellent technical support and J. Stavenhagen for providing the 4-20-20 construct. R.M.A. is an Irvington Institute fellow of the Cancer Research Institute. This work was performed with support from Centarus Pharmaceuticals and NIH to J.V.R. and by NIH grant GM60938 to J.C.P. J.V.R. is a founder and shareholder in Centarus Pharmaceuticals.